ReviewFrontiers in medicine2020
Portopulmonary Hypertension: From Bench to Bedside.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- Long-Term Outcome of Pulmonary Artery Hypertension-Specific Therapy in Patients With Portopulmonary Hypertension: A Multi-Institutional Database Case Series Study.Pulmonary circulation · 2026Article
- Broiler Ascites Syndrome as a Potential Spontaneous Animal Model for Human Pulmonary Arterial Hypertension: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Case Report: Vascular abdominal pain in systemic sclerosis-chronic mesenteric ischemia from high-grade superior mesenteric artery stenosis with coexisting aortomesenteric narrowing.Frontiers in medicine · 2026Article
- Clinical aspects encountered in patients with portopulmonary hypertension.Medicine and pharmacy reports · 2025Review
- Porto-Pulmonary Hypertension and Hepato-Pulmonary Syndrome: Diagnostic Procedures and Therapeutic Management.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- Liver bypass in the development of pathogen-associated pulmonary vascular disease: contribution of mesocaval and portosystemic shunts.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- A rare case of idiopathic portal hypertension with portopulmonary hypertension occurred following splenectomy with a change in portal hemodynamics.Clinical journal of gastroenterology · 2025Article
- Echocardiographic Screening of Liver Transplant Candidates-Prevalence of Features of Portopulmonary Hypertension.Journal of clinical medicine · 2024Article
- Echocardiographic evaluation in patient candidate for liver transplant: from pathophysiology to hemodynamic optimization.Journal of anesthesia, analgesia and critical care · 2024Review
- Making Living-donor Liver Transplantation a Viable Option for Patients With Portopulmonary Hypertension.Transplantation direct · 2024Article
- Clinical outcomes of upfront combination therapy for portopulmonary hypertension.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- When Pulmonary Arterial Hypertension may be Associated with Portal Hypertension: A Case Report of Two Different Hepatic Disorders in One Patient with Pulmonary Hypertension.Current cardiology reviews · 2024Review
- The right ventricle outflow tract systolic function could predict the severity of the cirrhosis.Turkish journal of medical sciences · 2024Article
- [Pulmonary Complications in Patients with Liver Cirrhosis].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Article
- Portopulmonary Hypertension: An Updated Review.Transplantation direct · 2023Review
- Portopulmonary hypertension: Success with combined medical treatment.Respirology case reports · 2023Article
- Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2023Review
- Current clinical understanding and effectiveness of portopulmonary hypertension treatment.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portopulmonary hypertension (PoPH) is defined as pulmonary arterial hypertension (PAH) associated with portal hypertension and is a subset of Group 1 pulmonary hypertension (PH). PoPH is a cause of significant morbidity and mortality in patients with portal hypertension with or without liver disease. Significant strides in elucidating the pathogenesis, effective screening algorithms, accurate diagnoses, and treatment options have been made in past 20 years. Survival of PoPH has remained poor compared to IPAH and other forms of PAH. Recently, the first randomized controlled trial was done in this patient population and showed promising results with PAH specific therapy. Despite positive effects on hemodynamics and functional outcomes, it is unclear whether PAH specific therapy has a beneficial effect on long term survival or transplant outcomes. In this review, we will discuss the epidemiology, pathophysiology, clinical and hemodynamic characteristics of PoPH. Additionally, this review will highlight the lacunae in our current management strategy, challenges faced and will provide direction to potentially useful futuristic management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.